Eiger BioPharmaceuticals Inc (Nasdaq: EIGR), a company focused on the development and commercialisation of therapies for rare and ultra-rare diseases, announced yesterday that it has named Mark Mannebach, PhD, RPh as vice president of Global Regulatory Affairs.

Dr Mannebach has more than 30 years of experience in the pharmaceutical industry in leadership roles including Parke-Davis, Warner Lambert, Pharmacia, Baxter, and Pfizer.

Dr Mannebach was previously vice president of Global Regulatory Affairs and on the Executive Management Team at Covidien and Mallinckrodt Pharmaceuticals, and was most recently vice president of Global Regulatory Affairs and Quality Assurance at Charleston Laboratories.

David Cory, President and CEO of Eiger, said, 'Eiger's pipeline is now late-stage with planned global regulatory activities including an NDA and MAA for Progeria and Progeroid Laminopathies, enrollment of a global Phase 3 study for Lonafarnib in HDV, and End of Phase 2 meetings for Peginterferon Lambda in HDV and Avexitide in Post-Bariatric Hypoglycemia. Mark's global regulatory expertise and experience will strengthen our leadership team and execution. We look forward to Mark's strategic insights and contributions as we evolve into a commercial company.'